首页> 美国卫生研究院文献>Scientific Reports >Mapping discontinuous epitopes for MRK-16 UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein
【2h】

Mapping discontinuous epitopes for MRK-16 UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein

机译:将MRK-16UIC2和4E3抗体的不连续表位映射至人P-糖蛋白的细胞外环1和4

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

P-glycoprotein (P-gp), an ATP-dependent efflux pump, is associated with the development of multidrug resistance in cancer cells. Antibody-mediated blockade of human P-gp activity has been shown to overcome drug resistance by re-sensitizing resistant cancer cells to anticancer drugs. Despite the potential clinical application of this finding, the epitopes of the three human P-gp-specific monoclonal antibodies MRK-16, UIC2 and 4E3, which bind to the extracellular loops (ECLs) have not yet been mapped. By generating human-mouse P-gp chimeras, we mapped the epitopes of these antibodies to ECLs 1 and 4. We then identified key amino acids in these regions by replacing mouse residues with homologous human P-gp residues to recover binding of antibodies to the mouse P-gp. We found that changing a total of ten residues, five each in ECL1 and ECL4, was sufficient to recover binding of both MRK-16 and 4E3 antibodies, suggesting a common epitope. However, recovery of the conformation-sensitive UIC2 epitope required replacement of thirteen residues in ECL1 and the same five residues replaced in the ECL4 for MRK-16 and 4E3 binding. These results demonstrate that discontinuous epitopes for MRK-16, UIC2 and 4E3 are located in the same regions of ECL1 and 4 of the multidrug transporter.
机译:P-糖蛋白(P-gp)是一种ATP依赖的外排泵,与癌细胞中多药耐药性的发展有关。抗体介导的对人P-gp活性的阻断已显示可通过使耐药性癌细胞对抗癌药重新敏感来克服耐药性。尽管该发现具有潜在的临床应用价值,但尚未绘制与细胞外环(ECL)结合的三种人P-gp特异性单克隆抗体MRK-16,UIC2和4E3的表位。通过生成人鼠P-gp嵌合体,我们将这些抗体的表位定位到了ECL 1和4。然后,通过用同源人P-gp残基替换小鼠残基以恢复抗体与抗体的结合,从而鉴定了这些区域中的关键氨基酸。小鼠P-gp。我们发现,改变ECL1和ECL4中总共10个残基(每个5个)足以恢复MRK-16和4E3抗体的结合,表明存在一个共同的表位。但是,要恢复构象敏感的UIC2表位,需要替换ECL1中的13个残基,并替换ECL4中的5个残基,以结合MRK-16和4E3。这些结果表明,MRK-16,UIC2和4E3的不连续表位位于多药转运蛋白ECL1和4的相同区域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号